Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Asian Currencies Rise as Dollar Weakens; Yen Holds Steady Amid Japan Intervention Watch 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Brazil to Phase Out Gasoline Subsidy First as Diesel Support Stays Longer 
Turkey Vehicle Sales Fall 11.4% in June as Auto Market Weakens 
Goldman Sachs Says China Competition Weighs More on EU Growth Than Trade Deficit 
Australia Trade Balance Swings to Surprise Deficit as Imports Outpace Exports in May 
Moody’s Says Peru’s President-Elect Keiko Fujimori Could Boost Investor Confidence 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Trump Administration Declines USMCA Renewal, Opens Talks on New Trade Changes 
Meta Stock Jumps as AI Cloud Expansion Challenges AWS, Microsoft, and Google 
Japan Signals Readiness to Act on Yen as Intervention Speculation Grows 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
